Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phenotype-driven precision oncology in patient-derived tumor models predict therapeutic response in squamous cell carcinoma

ABSTRACT: Comparison of single-cell transcriptomic profiles of cell lines obtained from the primary and metastatic tumor from a single patient.

ORGANISM(S): Homo sapiens

PROVIDER: GSE84323 | GEO | 2017/07/12

SECONDARY ACCESSION(S): PRJNA329106

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Phenotype-driven precision oncology in patient-derived tumor models predict therapeutic response in squamous cell carcinoma

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-07-21 | GSE84676 | GEO

Phenotype-driven precision oncology in patient-derived tumor models predict therapeutic response in squamous cell carcinoma [expression]

Project description:Gene expression analysis of patient metastatic tumor derived cell lines.

2017-07-21 | GSE100123 | GEO

Phenotype-driven precision oncology in patient-derived tumor models predict therapeutic response in squamous cell carcinoma

Project description:Phenotype-driven precision oncology in patient-derived tumor models predict therapeutic response in squamous cell carcinoma

| PRJNA330817 | ENA

Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.

Project description: Not available

| S-EPMC5585361 | biostudies-literature

Patient-derived micro-organospheres (MOS) enable clinical precision oncology

Project description:Patient-derived xenografts (PDX) and organoids (PDO) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of Micro- Organospheres (MOS) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. A clinical study of newly diagnosed metastatic colorectal cancer (CRC) patients using a MOS-based precision oncology pipeline reliably predicted patient treatment outcome within 14 days, a timeline suitable for guiding treatment decisions in clinic. Furthermore, MOS capture original stromal cells and allow T cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T cell therapies on patient tumors.

2022-09-01 | GSE184242 | GEO

A single-cell based precision medicine approach using glioblastoma patient specific models

Project description:Glioblastoma (GBM) is a heterogeneous tumor made up of cell states that evolve over time. Here, we modeled tumor evolutionary trajectories during standard-of-care treatment using multi-omic single-cell analysis of a primary tumor sample, corresponding mouse xenografts subjected to standard of care therapy, and recurrent tumor at autopsy. We mined the multi-omic data with single cell SYstems Genetics Network AnaLysis (scSYGNAL) to identify a network of 52 regulators that mediate treatment-induced shifts in xenograft tumor-cell states that were also reflected in recurrence. By integrating scSYGNAL-derived regulatory network information with transcription factor accessibility deviations derived from single-cell ATAC-seq data, we developed consensus networks that modulate cell state transitions across subpopulations of primary and recurrent tumor cells. Finally, by matching targeted therapies to active regulatory networks underlying tumor evolutionary trajectories, we provide a framework for applying single-cell-based precision medicine approaches in a concurrent, adjuvant, or recurrent setting.

2022-07-01 | GSE189650 | GEO

HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology.

Project description: Not available

| S-EPMC5580716 | biostudies-literature

Automated eligibility screening and monitoring for genotype-driven precision oncology trials.

Project description: Not available

| S-EPMC6370254 | biostudies-literature

Precision oncology probe set for nomination of biomarker driven intervention opportunities in lung cancer

Project description:Diversity in the genetic lesions that drive cancer initiation and progression is extreme. In consequence, a pressing challenge is the development of pharmaceuticals that selectively target disease mechanisms within the appropriate cancer patients. To help delineate the landscape of opportunities that can address this challenge, we have employed a chemistry-first discovery paradigm for de novo identification of druggable targets linked to robust patient selection hypotheses. To do this, a 200,000 compound diversity-oriented chemical library was profiled across a heavily annotated test-bed of >100 cell models representative of the somatic lesions detected in lung cancer. 171 distinct chemical/genetic associations, exploiting disease-selective mechanistic vulnerabilities within a diverse array of biological systems, were discovered. These corresponded to both novel and known oncogenotypes detectable within significant patient populations that lack effective therapy. Chemically addressab le addictions to ciliogenesis in TTC21B mutants and GLUT8-dependent serine biosynthesis in KRAS/KEAP1 double mutants are prominent examples. These observations indicate a wealth of actionable opportunities within the complex molecular etiology of cancer. One chemical in the screen corrected with high expression levels of the positive regulator of the TLR pathway, PELI2, and high expression of PELI2 was predictive of chemical sensitivities outside the training set. SW151511 was thus selected for delineation of global changes in gene expression pattern in response to chemical perturbation. In this experiment, two SW151511-sensitive cells (H596 and H2122) and two SW151511-resistant cells (H661, HCC366) were treated for 24 hours with 10 uM of either chemical or DMSO. After which, microarray expression profiles were determined using Illumina BeadArray V4 and normalized with lumi in R bioconductor.

2018-08-09 | GSE104757 | GEO

A Single-Cell Tumor Immune Atlas for Precision Oncology

Project description:The tumor immune microenvironment is a main contributor to cancer progression and a promising therapeutic target for oncology. However, immune microenvironments vary profoundly between patients and biomarkers for prognosis and treatment response lack precision. A comprehensive compendium of tumor immune cells is required to pinpoint predictive cellular states and their spatial localization. We generated a single-cell resolved tumor immune cell atlas, jointly analyzing >500,000 cells from 217 patients and 13 cancer types, providing the basis for a patient stratification based on immune cell compositions. Projecting immune cells from external tumors onto the atlas facilitated an automated cell annotation system for a harmonized interpretation. To enable in situ mapping of immune populations for digital pathology, we developed SPOTlight, a computational tool that identified striking spatial immune cell patterns in tumor sections. We expect the atlas, together with our versatile toolbox for precision oncology, to advance currently applied stratification strategies for prognosis and immuno-therapy response.

2020-10-27 | GSE158803 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data